Live feed08:00:00·347dPRReleasevia QuantisnowRhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic ObesityByQuantisnow·Wall Street's wire, on your screen.RYTM· Rhythm Pharmaceuticals Inc.Health Care
